

In silico dynamics of COVID-19 phenotypes for optimizing clinical management

Chrysovalantis Voutouri

University of Cyprus

Mohammad Reza Nikmaneshi

Massachusetts General Hospital

C. Corey Hardin

Massachusetts General Hospital

Ankit B. Patel

Brigham and Women's Hospital

Ashish Verma

Brigham and Women's Hospital

Melin J. Khandekar

Massachusetts General Hospital

Sayon Dutta

Massachusetts General Hospital

Triantafyllos Stylianopoulos (✉ stylianopoulos.triantafyllos@ucy.ac.cy)

University of Cyprus

Lance L. Munn (✉ munn@steele.mgh.harvard.edu)

Massachusetts General Hospital

Rakesh K. Jain (✉ jain@steele.mgh.harvard.edu)

Massachusetts General Hospital

Research Article

Keywords: COVID-19, SARS-CoV-2, Systems Biology, Computational Model

Posted Date: September 3rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-71086/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Proceedings of the National Academy of Sciences on January 5th, 2021. See the published version at <https://doi.org/10.1073/pnas.2021642118>.

Abstract

Understanding the underlying mechanisms of COVID-19 progression and the impact of various pharmaceutical interventions is crucial for the clinical management of the disease. We developed a comprehensive mathematical framework based on the known mechanisms of the SARS-CoV-2 virus infection, incorporating the renin-angiotensin system and ACE2, which the virus exploits for cellular entry, key elements of the innate and adaptive immune responses, the role of inflammatory cytokines and the coagulation cascade for thrombus formation. The model predicts the evolution of viral load, immune cells, cytokines, thrombosis, and oxygen saturation based on patient baseline condition and the presence of co-morbidities. Model predictions were validated with clinical data from healthy people and COVID-19 patients, and the results were used to gain insight into identified risk factors of disease progression including older age, co-morbidities such as obesity, diabetes, and hypertension, and dysregulated immune response^{1,2}. We then simulated treatment with various drug classes to identify optimal therapeutic protocols. We found that the outcome of any treatment depends on the sustained response rate of activated CD8⁺ T cells and sufficient control of the innate immune response. Furthermore, the best treatment – or combination of treatments – depends on the pre-infection health status of the patient. Our mathematical framework provides important insight into SARS-CoV-2 pathogenesis and could be used as the basis for personalized, optimal management of COVID-19.

Chrysovalantis Voutouri and Mohammad Reza Nikmaneshi contributed equally to this work

Background

COVID-19 has created unprecedented challenges for the healthcare system, and until an effective vaccine is developed and made widely available, treatment options are limited. A challenge to the development of optimal treatment strategies is the extreme heterogeneity of presentation. Infection with SARS-CoV-2 results in a syndrome that ranges in severity from asymptomatic to multi-organ failure and death. In addition to local complications in the lung, the virus can cause systemic inflammation and disseminated micro thrombosis, which can cause stroke, myocardial infarction or pulmonary emboli³⁻⁶. Risk factors for poor COVID-19 outcome include advanced age, obesity, diabetes and hypertension^{1,7-13}.

Computational analyses can provide insights into the transmission, control, progression and underlying mechanisms of infectious diseases. Indeed, epidemiological and statistical modeling has been used for COVID-19, providing powerful insights into co-morbidities, transmission dynamics and control of the disease¹⁴⁻¹⁷. However, to date, these analyses have been population dynamics models of SARS-CoV-2 infection and transmission or correlative analyses of COVID-19 comorbidities and treatment response. Simple viral dynamics models have been also developed and used to predict the SARS-CoV-2 response to anti-viral drugs^{18,19}. All these models, however, do not explicitly consider the biological or physiological mechanisms underlying disease progression or the time-course of response to various therapeutic interventions.

Several therapies targeting various aspects of COVID-19 pathogenesis have been proposed and have either completed – or are currently being tested in – clinical trials²⁰. Despite strong biologic rationale, these treatments have generally produced conflicting results in the clinic. For example, the initial trials of the anti-viral remdesivir have been mixed: the original trial from China failed²¹, while the recent trial in the US is more encouraging and has led to

the approval of remdesivir in the US and other countries²². Other anti-viral drugs alone or in combination are also showing promise²³.

Other potential treatments include anti-inflammatory drugs and anti-thrombotic agents. Because of the systemic inflammation seen in many patients, anti-inflammatory drugs have been tested, including anti-IL6/IL6R therapy (e.g., tocilizumab, siltuximab) and anti-JAK1/2 drugs (e.g. baricitinib). It is not clear if these drugs will be effective as stand-alone treatments, particularly after the recent failure of tocilizumab in a phase III trial^{3,24-26}. In addition, given that a common complication of COVID-19 is the development of coagulopathies with microvascular thrombi potentially leading to the dysfunction of multiple organ systems^{4,5}, anti-thrombotic drugs (e.g., low molecular weight heparin) are being tested. Recognizing the interactions of COVID-19 with the immune system²⁷, the corticosteroid dexamethasone have been tested, showing some promising results. Given the large range of patient comorbidities, disease severities, and variety of complications such as thrombosis, it is likely that patients will have heterogeneous responses to any given therapy, and such heterogeneity will continue to be a challenge for clinical trials of unselected COVID-19 patients²⁸.

Here, we developed a systems biology-based mathematical model to address this urgent need. Our model incorporates the known mechanisms of SARS CoV-2 pathogenesis and the potential mechanisms of action of various therapeutic interventions that have been tested in COVID-19 patients. In previous work, we have exploited angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEis) for the improvement of cancer therapies and developed mathematical models of the renin-angiotensin system in the context of cancer desmoplasia²⁹⁻³². Using a similar approach, we developed a detailed model that includes lung infection by the SARS-CoV-2 virus and a pharmacokinetic/pharmacodynamic (PK/PD) model of infection and thrombosis to simulate events that take place throughout the body during COVID-19 progression (Figure 1 and Supplementary Figure 1). The model is first validated against clinical data of healthy people and COVID-19 patients and then used to simulate disease progression in patients with specific co-morbidities. Subsequently, we present model predictions for various therapies currently employed for treatment of COVID-19 alone or in combination, and we identify protocols for optimal clinical management for each of the clinically-observed COVID-19 phenotypes.

Model Description

The model includes SARS-CoV-2 infection, the renin angiotensin system (RAS), inflammatory and anti-inflammatory cytokines, innate and adaptive immune cells, and factors involved in the coagulation cascade (Fig. 1). SARS-CoV-2 enters the cell by docking to ACE2, a key component of the RAS. ACE2 can be membrane-bound or soluble, and it regulates inflammation by converting Ang II to Ang 1-7 and Ang I to Ang 1-9; as opposed to Ang I and Ang II, which lead to inflammation. Ang 1-7 and Ang 1-9 have anti-inflammatory effects. Intracellular virus initiates inflammatory pathways through toll-like receptors and NFkB, which produces interferons and other inflammatory cytokines. The viral antigens, along with inflammatory cytokines, cause activation of naïve T cells, creating virus-specific T effector cells. T cell activation is controlled by viral antigen strength and the presence of PD-L1 / PD-1 inhibition. We combine inflammatory cytokines into a single variable, but explicitly account for IL6 production via the trans pathway in epithelial and endothelial cells and the canonical pathway in immune cells. In the presence of inflammatory cytokines and virus, neutrophils can produce neutrophil extracellular traps (NETs).

Because the virus can infect endothelial cells, we also consider viral dissemination via the blood stream, and the possibility of systemic infection and thrombosis. We include the major organs in a PK/PD model, with physiological

blood flow patterns explicitly modeled. Infection of endothelial cells, combined with high levels of inflammatory cytokines in the plasma, can result in thrombosis. Damage to virally-infected endothelial cells and the production of NETs can exacerbate the thrombosis, and microthrombi can enter the blood stream to accumulate in other organs, including the brain, heart and lung. We use a simplified model of the coagulation pathways, assuming that formation of microthrombi is proportional to the number of infected endothelial cells, the presence of neutrophil NETs, and the level of inflammatory cytokines. Transport of oxygen from the alveolar space to the blood vessels in the lung is calculated using a modified diffusion model, which accounts for damage-induced thickening of the alveolar membrane³³.

Results

Model validation with data of healthy people and various COVID-19 phenotypes.

Model predictions were validated with clinical data from healthy humans and severe COVID-19 patients³⁴⁻³⁶. Figure 2A-D presents the comparison showing agreement between model predictions and clinical data for Angiotensin II (Ang II), Neutrophils, CD8⁺ T cells and IL6 levels. Figure 2E further validates model predictions for the evolution of IL6 in COVID-19 patients admitted to the intensive care unit of Massachusetts General Hospital³⁷.

Subsequently, we focused on the clinically observed phenotypes of COVID-19. We used the model to predict the time evolution of critical disease variables, namely the virus load, levels of IL6 and other pro-inflammatory cytokines, the formation of microthrombi in the lung, the numbers of neutrophils, macrophages and activated cytotoxic CD8⁺ T cells, and the blood oxygen saturation (SpO₂). The COVID-19 patient phenotypes considered include young patients (age<35), older patients (age>65) who more frequently require hospitalization, female patients, as well as patients with co-morbidities such as hypertension, obesity and diabetes, and patients with a dysregulated immune response, whose condition is characterized by high levels of pro-inflammatory cytokines (Figure 3). Supplementary Table 2 presents the model parameters that were modified from the baseline values to account for these various patient phenotypes. In all phenotypes, the viral load increases during early lung infection with divergent trajectories seen after day 5, depending on the levels of activated T cells. In younger patients (age<35) with a healthy immune system, the sustained recruitment of T cells results in a reduction in viral load and inflammation, as well as a decrease in neutrophils and macrophages. All these effects cause a significant reduction in the formation of thrombi and restoration of oxygenation.

In general, the simulations resulting in poor outcome were due to increased baseline inflammation or more active innate immune response combined with less effective adaptive immunity. This was the case –in varying degrees– for older patients and those with diabetes, obesity, hypertension, and dysregulated immunity (“hyper-inflamed”; see supplement Table 2 for the parameters varied in each population). In the latter case, the adaptive immune response is intact and clears the virus, but the innate immune response is sustained, perpetuating inflammation, thrombosis and hypoxemia.

An outstanding question is why males tend to have more severe COVID-19 disease compared with females³⁸. Proposed mechanisms include the higher CD4/CD8 T cell ratio in females³⁹ and androgen-induced differences in susceptibility to viral entry into the cells due to higher TMPRSS levels in males⁴⁰. To simulate COVID-19 in an older female, we decreased the production of naïve T cells and the rate of virus entry into the cells⁴¹. The simulations predict lower viral load compared with the older males, with correspondingly less inflammation and hypoxemia.

These results suggest that reduced viral entry into cells due to lower TMPRSS2 level can explain the improved outcomes in females—even if the adaptive immune response is not as vigorous³⁸.

Efficacy of current treatments on COVID-19 progression

To identify optimal treatment protocols, we simulated the effects of the various treatments currently being investigated for COVID-19. We first simulated a patient of age >65 years (assumed to have baseline inflammation and impaired T effector cell function) and performed simulations of various treatments given at early (day 3, SpO₂ ≥92%) and late (day 7, SpO₂ <90%) stages of the disease. For the purpose of the simulations, day 0 is the time of arrival of the virus in the lung, so significant symptoms are expected starting around day 3. Simulating treatment on day 3 represents early treatment (e.g., upon hospital admission); later treatment (day 7) could be due to delayed diagnosis/hospital admission or in response to disease progression. Treatments that were considered include: heparin (anti-coagulant), anti-viral therapy, dexamethasone, ARBs, ACEi, hrACE2, anti-IL6 and anti-IL6R treatment. Supplementary Table 2 summarizes the model parameters that were modified from their baseline values to account for the different treatments. The severity of disease was primarily assessed based on the degree of hypoxemia and thrombus formation. The dynamics of the disease progression are shown in Supplementary Figure 2 and the values at the last day of the simulation (day 20) are summarized in Table 1.

Unsurprisingly, we found that heparin decreases thrombus formation and improves oxygenation when administered during early stages of disease, but has no effect on viral load. The anti-viral remdesivir is effective in reducing viral load in early stages, but less effective in reducing thrombus formation and improving oxygenation. Interestingly, dexamethasone is helpful when started later, but early administration can prevent the production of activated T cells, making it difficult to reduce the viral load. This mirrors the data from the RECOVERY trial, where dexamethasone was demonstrated to improve outcomes in patients requiring ventilatory support, but not in those with milder symptoms. These simulations also identify IL-6 directed therapies as potential therapeutics that may benefit patients if started early in the disease course. As far as inhibitors of the RAS are concerned, both ARBs and ACEi show modest benefits only when administered early, whereas the model predicts a significant benefit from the use of hrACE2 on day 7, but not day 3.

Optimizing clinical management of COVID-19 by combining therapies

Because of the diverse mechanisms involved in COVID-19 pathogenesis, clinical management currently involves combination of multiple therapies in an effort to optimize therapeutic outcomes. To investigate the effects of combination treatments, we performed simulations combining various therapeutic approaches in pairs, using the best treatment time for each single treatment (i.e., day 3 or day 7, Table 1). We also accounted for older patients and those with co-morbidities and dysregulated immune responses. Table 2 presents a summary of the combined treatments for older patients (>65 years); the results for the other COVID-19 phenotypes are presented in Supplementary Tables 3-6. According to the model predictions, effective clinical management of older patients (with some baseline inflammation and impaired adaptive immunity) involves combination of heparin (day 3) with dexamethasone (day 7), which can improve oxygenation and decrease micro-thrombosis significantly; however, these treatments have little effect on viral load. For patients with obesity or hypertension, the combination of heparin with dexamethasone is again beneficial compared to other treatments. In addition, the use of anti-IL6/anti-

IL6R therapy could also be considered in both these patient populations. For diabetic patients, the combination of heparin with dexamethasone can improve oxygenation and thrombus formation similar to the other scenarios. Other treatments predicted to be beneficial for this phenotype is the combination of dexamethasone with hrACE2 or anti-IL6/anti-IL6R. These combination therapies in diabetic patients can treat hypoxemia and coagulation but also reduce the viral load. For patients with dysregulated immune systems, early blockade of IL6 combined with dexamethasone on day 7 give optimal results; anti-IL6/anti-IL6R combined with anti-viral therapy and/or heparin could also be considered.

Discussion

COVID-19 is a complex disease that can affect multiple organs and is characterized by extremely heterogenous presentation. As with other critical care syndromes such as septic shock, and non- COVID-19 ARDS disease severity results from a complex interplay of viral replication, adaptive and maladaptive immune response and patient comorbidities. Such heterogeneity is a challenge to the development of effective therapies as candidate approaches may elicit different responses depending on the phase of illness or patient comorbidities. Because of the complexity of the underlying mechanisms and interactions among the various components involved in the disease, the response of COVID-19 patients to any treatment is not intuitive and for that reason we developed a highly sophisticated mathematical model to provide insights into the underlying mechanisms and predict optimal treatment strategies.

A main conclusion of our study is that disease progression and outcome of any treatment largely depends on the response rate of activated CD8⁺ T cells and subsequent control of the innate immune system response. A sustained activation of CD8⁺ T cells along with the control of the populations of neutrophils and macrophages can lead to a decrease in viral load and inflammation. This, in turn, will improve arterial oxygen saturation levels due to the decreased endothelial damage and micro thrombosis, and limited formation of neutrophil extracellular traps (NETs)⁴². In line with these conclusions about the underlying mechanisms of the disease, our model predicts that anti-viral and anti-inflammatory drugs that were first employed to treat COVID-19 might have limited efficacy, depending on the stage of the disease progression. Furthermore, our simulations suggest that an optimal approach would be to enhance the adaptive immune response in the early stages while limiting harmful inflammation in the later stages of the disease. We also found that addition of heparin to the treatment regimen of COVID-19 can improve therapeutic outcomes. In case of patients with co-morbidities (obesity, diabetes, hypertension) or dysregulated immunity, the treatment regimen could further include anti-inflammatory drugs (e.g., anti-IL6/anti-IL6R) and RAS inhibitors and hrACE2 for the diabetic patients in particular.

Our mathematical modeling framework is subject to certain limitations. The model is able to account for the currently-known components and interactions involved in disease pathogenesis but results in a large number of model parameters. Most of the values of these parameters were taken from the literature. However, because COVID-19 is a new disease, many of the parameter values are not known yet. For these parameters, it was necessary to make reasonable assumptions about their values, as summarized in Supplementary Table 1. We further validated the model predictions quantitatively with available clinical data for healthy and infected humans and qualitatively based on clinical observations for the different COVID-19 phenotypes. Our mathematical framework can be further refined as new mechanisms and more data become available and can be adapted for other diseases similar to COVID-19.

Another limitation of the model is that it does not account for adverse effects of the various treatments considered in this study, which could affect the therapeutic outcome. For instance, heparin use might be associated with hemorrhage and RAS inhibitors can reduce blood pressure. Even though incorporation of adverse effects could be important, they would not affect the basic conclusions of the study and were omitted to avoid adding further complexity to the model. In conclusion, this study presents a mathematical representation of the known mechanisms of COVID-19 and could be utilized by the scientific community as a useful tool for further understanding the disease and investigating the benefits of treatments on a patient-specific basis.

Methods

A detailed description of model equations, the description and values of model parameters and the solution strategy are provided in the Supplementary Information. The mathematical model consists of two components: a detailed model of lung infection by the SARS-CoV-2 virus and a pharmacokinetic/pharmacodynamic (PK/PD) model of COVID-19 infection and thrombosis to simulate events that happen throughout the body (Figure 1). The lung model incorporates the infection of epithelial and endothelial cells by the SARS-CoV-2 virus through ACE2 modulation and activity, the release of pro-inflammatory cytokines and the entire RAS. Cytokines that are central to COVID-19 (e.g., IL-6) are explicitly accounted for in the model, incorporating all known signaling pathways, such as the canonical and trans signaling pathway of IL-6 and its interaction with IL-6r and soluble IL-6r. Additional innate immune cells, specifically neutrophils and macrophages, are incorporated into our model along with the interaction of immune cells with viral particles and infected cells as well as the formation of neutrophil extracellular traps (NETs). The model incorporates the recruitment of cytotoxic T cells by the infected cells and by IL-6 as well as the virus killing of cytotoxic T cells. In addition, the model accounts for the role of immune cells in modulating the expression of pro-inflammatory cytokines. Subsequent events, such as the impairment of the vascular network owing to the infection of endothelial cells by the SARS-CoV-2 virus and the resulting changes in blood oxygenation are also included.

To study how the virus affects systemic events, such as inflammation and thrombosis, we coupled the lung model with a PK/PD model of viral infection. The PK/PD model represents the major organs of the body as compartments connected in an anatomical manner by the blood and lymphatic circulations (Supplementary Figure 1). The organ compartments are then further subdivided into vascular and extravascular sub-compartments, and each organ has a draining lymph node compartment. Briefly, the main transport processes for the biochemical species include: i) convective and diffusive transport across capillary walls, ii) reversible, non-saturable, nonspecific binding in the extravascular compartments, iii) reversible, and saturable, specific binding of virus to endothelial cells, and probabilistic infection of bound cells. Any infected cell generates microthrombi, which enter the circulation and can accumulate in target organs including brain, heart and lung. Each species can be produced, bound or degraded within each compartment. Blood flow is distributed according to known flows through each organ, and the overall mass balance allows calculation of the concentration of each species in each compartment over time. The PK/PD model includes the following key processes involved in the trafficking of viruses: i) transport from the lung via the systemic circulation, ii) entry into endothelial cells via binding to ACE2, iii) entry into the cell and replication, iv) exit from the cell and entry into the blood circulation. The important outputs of the model are the level of thrombosis in each organ and the viral load. When coupled with the lung model, we are able to analyze the dynamics of these readouts in light of local lung pathologies and predicted cytokine levels.

The model consists of a set of 90 partial and ordinary differential equations. The values of the model parameters are summarized in Supplementary Table 1. We simulated COVID-19 infection and progression within a period of 20 days. Notice that the model does not account for the first stages of virus infection of the upper respiratory tract but

from the time the virus has infected the lungs. Therefore, day 0 of the simulations corresponds to the initiation of lung infection. For the formulation of the model and the solution of the equations, the commercial finite elements software COMSOL Multiphysics v.5.5 was used. The computational finite element mesh employed in the present study consisted of 2,440 elements resulting in 1,201,044 degrees of freedom. The solution was tested and found to be mesh-independent, the PARDISO solver was selected for the solution of the model equations and the total solution time was approximately 30 minutes.

Data availability. All data supporting the findings of this study are available in the paper and the Supplementary Information.

Code availability. The COMSOL code will become available in Zenodo upon acceptance of the manuscript.

Declarations

Acknowledgments

Rakesh Jain's research is supported by R01-CA208205, and U01-CA 224348, Outstanding Investigator Award R35-CA197743 and grants from the National Foundation for Cancer Research, Jane's Trust Foundation, American Medical Research Foundation and Harvard Ludwig Cancer Center. Lance Munn's research is supported by R01-CA2044949. Triantafyllos Stylianopoulos's research is supported by the European Research Council (ERC-2018-PoC-838414, ERC-2019- CoG-863955). Ankit Patel is supported by American Society of Nephrology Joseph A. Carlucci Research Fellowship.

Author contributions

C.V., M.R.N. performed research, T.S., L.L.M., and R.K.J. designed research, C.C.H, A.B.P., A.V., M.J.K., S.D., T.S., L.L.M., and R.K.J supervised model development, all authors analyzed data and wrote the article.

These authors declare the following competing interests:

R.K.J. received honorarium from Amgen; consultant fees from Chugai, Merck, Ophthotech, Pfizer, SPARC, SynDevRx, XTuit; owns equity in Accurius, Enlight, Ophthotech, SynDevRx; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund. Neither any reagent nor any funding from these organizations was used in this study. A.B.P. has received fellowship funding from Relypsa, Inc. LLM owns equity in Bayer AG and consultant for SimBiosys. Neither any reagent nor any funding from these organizations was used in this study.

The remaining authors declare no competing interests.

Materials & Correspondence

Corresponding authors: T.S. tstylian@ucy.ac.cy, L.L.M. munn@steele.mgh.harvard.edu, and

R.K.J. jain@steele.mgh.harvard.edu

References

1. Williamson, E. J. *et al.* OpenSAFELY: factors associated with COVID-19 death in 17 million patients. *Nature*, doi:10.1038/s41586-020-2521-4 (2020).
2. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062, doi:10.1016/S0140-6736(20)30566-3 (2020).
3. Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. *Science*, eabb8925, doi:10.1126/science.abb8925 (2020).
4. Oxley, T. J. *et al.* Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med* **382**, e60, doi:10.1056/NEJMc2009787 (2020).
5. Paranjpe, I. *et al.* Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. *J Am Coll Cardiol* **76**, 122-124, doi:10.1016/j.jacc.2020.05.001 (2020).
6. Lax, S. F. *et al.* Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series. *Ann Intern Med*, doi:10.7326/M20-2566 (2020).
7. Stefan, N., Birkenfeld, A. L., Schulze, M. B. & Ludwig, D. S. Obesity and impaired metabolic health in patients with COVID-19. *Nat Rev Endocrinol*, doi:10.1038/s41574-020-0364-6 (2020).
8. Sattar, N., McInnes, I. B. & McMurray, J. J. V. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation*, doi:10.1161/CIRCULATIONAHA.120.047659 (2020).
9. Dai, *et al.* Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. *Cancer Discovery*, doi:10.1158/2159-8290.CD-20-0422 (2020).
10. Miyashita, H. *et al.* Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City. *Annals of Oncology* **in press** (2020).
11. Paranjpe, I. *et al.* Clinical Characteristics of Hospitalized Covid-19 Patients in New York *medRxiv*, doi:10.1101/2020.04.19.20062117 (2020).
12. Gupta, S. *et al.* Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. *JAMA Intern Med*, doi:10.1001/jamainternmed.2020.3596 (2020).
13. Grasselli, G. *et al.* Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med*, doi:10.1001/jamainternmed.2020.3539 (2020).
14. Kucharski, A. J. *et al.* Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *Lancet Infect Dis* **20**, 553-558, doi:10.1016/S1473-3099(20)30144-4 (2020).
15. Giordano, G. *et al.* Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. *Nat Med* **26**, 855-860, doi:10.1038/s41591-020-0883-7 (2020).
16. Prem, K. *et al.* The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *Lancet Public Health* **5**, e261-e270, doi:10.1016/S2468-2667(20)30073-6 (2020).
17. Hao, X. *et al.* Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature*, doi:10.1038/s41586-020-2554-8 (2020).
18. Goncalves, *et al.* Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. *CPT Pharmacometrics Syst Pharmacol*, doi:10.1002/psp4.12543 (2020).
19. Wang, S. *et al.* Modeling the viral dynamics of SARS-CoV-2 infection. *Math Biosci* **328**, 108438, doi:10.1016/j.mbs.2020.108438 (2020).

20. Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A *JAMA*, doi:10.1001/jama.2020.6019 (2020).
21. Wang, Y. *et al.* Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo- controlled, multicentre trial. *The Lancet*, doi:10.1016/S0140-6736(20)31022-9 (2020).
22. Beigel, J. H. *et al.* Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med*, doi:10.1056/NEJMoa2007764 (2020).
23. Hung, I. F.-N. *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* [https://doi.org/10.1016/S0140-6736\(20\)31042-4](https://doi.org/10.1016/S0140-6736(20)31042-4), doi:10.1016/S0140- 6736(20)31042-4.
24. Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the *Int J Antimicrob Agents*, 105954, doi:10.1016/j.ijantimicag.2020.105954 (2020).
25. Cantini, F. *et al.* Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. *J Infect*, doi:10.1016/j.jinf.2020.04.017 (2020).
26. Favalli, E. G., Biggioggero, M., Maioli, G. & Caporali, R. Baricitinib for COVID-19: a suitable treatment? *Lancet Infect Dis*, doi:10.1016/S1473-3099(20)30262-0 (2020).
27. Bert, N. L. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*, doi:<https://doi.org/10.1038/s41586-020-2550-z> (2020).
28. Iwashyna, J. *et al.* Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. *Am J Respir Crit Care Med* **192**, 1045-1051, doi:10.1164/rccm.201411-2125CP (2015).
29. Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. *Proc Natl Acad Sci U S A* **108**, 2909-2914 (2011).
30. Chauhan, V. P. *et al.* Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. *Nature Communications* **4**, 10.1038/ncomms.3516 (2013).
31. Chauhan, V. P. *et al.* Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer *Proc Natl Acad Sci U S A* **116** 10674-10680 (2019).
32. Zhao, Y. *et al.* Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. *Proc Natl Acad Sci U S A* **116**, 2210- 2219, doi:10.1073/pnas.1818357116 (2019).
33. Roy, K. & Secomb, T. W. Theoretical analysis of the determinants of lung oxygen diffusing capacity. *J Theor Biol* **351**, 1-8, doi:10.1016/j.jtbi.2014.02.009 (2014).
34. Liu, N., Hong, Y., Chen, R.-G. & Zhu, H.-M. High rate of increased level of plasma Angiotensin II and its gender difference in COVID-19: an analysis of 55 hospitalized patients with COVID-19 in a single hospital, WuHan, *MedRxiv* <https://doi.org/10.1101/2020.04.27.20080432> (2020).
35. Herold, *et al.* Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol* **146**, 128-136 e124, doi:10.1016/j.jaci.2020.05.008 (2020).
36. Chen, X. *et al.* Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *Clin Infect Dis*, doi:10.1093/cid/ciaa449 (2020).

37. Ziehr, D. R. *et al.* Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study. *Am J Respir Crit Care Med* **201**, 1560-1564, doi:10.1164/rccm.202004-1163LE (2020).
38. Montopoli, *et al.* Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). *Ann Oncol* **31**, 1040-1045, doi:10.1016/j.annonc.2020.04.479 (2020).
39. Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. *Nat Rev Immunol* **16**, 626-638, doi:10.1038/nri.2016.90 (2016).
40. Stopsack, K. H., Mucci, L. A., Antonarakis, E. S., Nelson, P. S. & Kantoff, P. W. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? *Cancer Discov* **10**, 779-782, doi:10.1158/2159-8290.CD-20-0451 (2020).
41. Takahashi, T. *et al.* Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. *medRxiv*, doi:10.1101/2020.06.06.20123414 (2020).
42. Barnes, B. J. *et al.* Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med* **217**, doi:10.1084/jem.20200652 (2020).

Tables

Table 1. Summary of model predictions for the therapeutic outcome of currently employed treatments initiated either in the beginning (day 3) of the disease or later (day 7). The table presents the results at the end of the simulation (day 20). Values have been normalized to the corresponding initial values except for SpO₂.

	Age<35	Age>65	Heparin, day3	Heparin, day7	Anti-viral, day3	Anti-viral, day7	Dex., day3	Dex., day7	ARBs, day3	ARBs, day7	ACEi, day3	ACEi, day7	hrACE2, day3	hrACE2, day7	anti-IL6, day3	anti-IL6, day7	anti-IL6R, day3	anti-IL6R, day7
SpO ₂ (%)	95	82	91	83	90	88	88	92	87	86	91	88	86	94	93	90	93	87
Microthrombosis in Lung	1.26	5.58	1.79	2.57	2.72	3.75	4.36	2.25	3.69	4.66	3.57	4.48	3.12	2.35	2.45	3.25	2.08	3.41
Inflammatory Cytokines	1.30	3.87	1.42	1.63	2.12	2.65	1.74	1.52	2.08	2.75	2.41	3.18	2.61	1.38	1.70	2.35	1.74	2.55
T eff cells	1.38	1.00	1.32	1.08	1.15	1.05	0.98	1.29	1.21	1.06	1.25	1.06	1.09	1.31	1.11	1.07	1.27	1.02
IL-6	1.22	4.68	1.56	1.95	2.52	4.15	2.25	1.42	2.08	2.95	1.85	3.56	3.25	1.74	1.68	2.74	1.45	2.65
Viral Load	1.18	7.45	5.85	6.35	1.55	4.15	3.75	2.36	3.56	4.44	3.32	5.08	3.89	2.08	2.22	3.15	2.45	2.89
Neutrophils	1.18	2.30	1.22	1.74	1.66	1.53	1.95	1.22	1.80	2.08	1.76	2.18	1.58	1.21	1.48	1.91	1.32	1.69
Macrophages	1.22	5.15	2.08	3.15	2.42	3.31	3.98	1.42	2.28	4.25	3.65	4.35	3.83	2.01	1.58	2.65	1.74	2.79




Table 2. Summary of model predictions for the therapeutic outcome of combined treatments for patients > 65 years old. The table presents the results at the end of the simulation (day 20). Values have been normalized to the corresponding initial values except for SpO₂.

SpO ₂ (%)	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	82	91	90	92	87	90	93	92	93
Heparin, day3			91	94	92	92	93	93	93
Anti-viral, day3			92	90	90	93	93	93	93
Dex., day7				92	93	94	94	94	94
ARBs, day3					90	93	92	92	92
ACEi, day3						93	92	92	92
hrACE2, day7							93	94	94
anti-IL6, day3								93	93
anti-IL6R, day3									93

T eff cells	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	1.00	1.32	1.15	1.29	1.21	1.25	1.31	1.11	1.27
Heparin, day3			1.23	1.36	1.28	1.32	1.33	1.15	1.2
Anti-viral, day3				1.33	1.25	1.37	1.32	1.41	1.35
Dex., day7					1.42	1.28	1.39	1.35	1.43
ARBs, day3						1.27	1.26	1.23	1.24
ACEi, day3							1.29	1.27	1.25
hrACE2, day7								1.35	1.45
anti-IL6, day3									1.49
anti-IL6R, day3									

Lung Microthrombi	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	5.58	1.79	2.72	2.25	3.69	3.57	2.35	2.45	2.08
Heparin, day3			1.68	1.63	1.77	1.72	1.62	1.53	1.47
Anti-viral, day3				2.15	2.54	2.59	1.97	1.82	1.75
Dex., day7					1.72	1.88	1.63	1.54	1.77
ARBs, day3						3.38	2.22	2.31	1.95
ACEi, day3							2.32	2.36	2.01
hrACE2, day7								2.28	2.13
anti-IL6, day3									1.74
anti-IL6R, day3									


IL6	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	4.68	1.56	2.52	1.42	2.08	1.85	1.74	1.68	1.45
Heparin, day3			1.48	1.11	1.32	1.35	1.22	1.17	1.12
Anti-viral, day3				1.33	1.2	1.23	1.41	1.32	1.35
Dex., day7					1.25	1.26	1.17	1.22	1.25
ARBs, day3						1.75	1.62	1.56	1.42
ACEi, day3							1.56	1.52	1.31
hrACE2, day7								1.32	1.26
anti-IL6, day3									1.2
anti-IL6R, day3									

Inflammatory Cytokines	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	3.87	1.42	2.12	1.52	2.08	2.41	1.38	1.70	1.74
Heparin, day3			1.32	1.12	1.38	1.35	1.22	1.35	1.26
Anti-viral, day3				1.38	1.87	1.92	1.35	1.62	1.68
Dex., day7					1.41	1.53	1.24	1.35	1.28
ARBs, day3						1.98	1.32	1.62	1.64
ACEi, day3							1.28	1.58	1.52
hrACE2, day7								1.23	1.25
anti-IL6, day3									1.34
anti-IL6R, day3									

Viral Load	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	7.45	5.85	1.55	2.36	3.56	3.32	2.08	2.22	2.45
Heparin, day3			1.53	2.23	3.25	3.17	1.98	2.15	2.36
Anti-viral, day3				1.08	1.35	1.32	1.45	1.42	1.55
Dex., day7					1.95	1.89	1.87	1.82	1.52
ARBs, day3						3.15	1.94	1.87	1.82
ACEi, day3							1.84	1.75	1.68
hrACE2, day7								1.68	1.52
anti-IL6, day3									1.46
anti-IL6R, day3									

Neutrophils	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	2.30	1.22	1.66	1.22	1.80	1.76	1.21	1.48	1.32
Heparin, day3			1.2	1.14	1.18	1.12	1.15	1.18	1.16
Anti-viral, day3				1.21	1.62	1.58	1.18	1.35	1.16
Dex., day7					1.18	1.14	1.11	1.15	1.18
ARBs, day3						1.67	1.15	1.37	1.24
ACEi, day3							1.17	1.42	1.28
hrACE2, day7								1.18	1.16
anti-IL6, day3									1.11
anti-IL6R, day3									

Macrophages	Age>65	Heparin, day3	Anti-viral, day3	Dex., day7	ARBs, day3	ACEi, day3	hrACE2, day7	anti-IL6, day3	anti-IL6R, day3
Age>65	5.15	2.08	2.42	1.42	2.28	3.65	2.01	1.58	1.74
Heparin, day3			1.77	1.35	1.98	1.88	1.68	1.32	1.25
Anti-viral, day3				1.24	2.14	2.35	1.65	1.37	1.31
Dex., day7					1.25	1.35	1.22	1.28	1.35
ARBs, day3						2.08	1.87	1.48	1.64
ACEi, day3							1.62	1.52	1.68
hrACE2, day7								1.35	1.32
anti-IL6, day3									1.28
anti-IL6R, day3									



Figures




Figure 1

Schematic of the detailed lung model. The model incorporates the virus infection of epithelial and endothelial cells, the RAS, T cells activation and immune checkpoints, the known IL6 pathways, neutrophils and macrophages, as well as the formation of NETs, and the coagulation cascade. The lung model is coupled with a PK/PD model for the virus and thrombi dissemination through the body.




Figure 2

Validation of the model. A-B) Model comparison with clinical data for healthy, uninfected people and for severe COVID-19 patients taken from pertinent studies 34-36. E) Comparison of model predictions with IL6 clinical data from patients hospitalized at the Massachusetts General Hospital. The data were taken at day 1 and day 3 from the time of patient's admission to the Intensive Care Unit (ICU).




Figure 3

Dynamics of disease progression. Time evolution of key model variables: viral load, IL6 concentration, pro-inflammatory cytokines concentration, activated T cells, microthrombosis in the lung, saturated oxygen levels, neutrophils and macrophages for young (<35 years old) and old (>65 years old) patients, females and patients with co-morbidities: hypertension, obesity and diabetes, as well as for hyper-inflamed patients and for anti-androgen treatment. Values have been normalized to the corresponding initial values except for S(Po2).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupportingMaterial.pdf](#)